samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > medicon valley - the scandinavian hotspot
PUBLICATIONS
European Biopharmaceutical Review

Medicon Valley - The Scandinavian Hotspot

Medicon Valley encompasses Skåne in southern Sweden and Copenhagen in Denmark, and is home to no less than 60 per cent of Scandinavia's biotechnology and pharmaceutical industries. More than 54,000 people in Medicon Valley work within the medical industry, including 5,000 researchers.Medicon Valley ranks number three in Europe in the biomedicine field, after London and Paris, and the region has probably the highest number of biotech companies per capita in the world. Sweden and Denmark are ranked number two and three in Europe when it comes to R&D expenditure per capita in the pharmaceutical industry, and Denmark and Sweden are, per capita, ranked number three and five in terms of world pharmaceutical exports. Medicon Valley has ample capital for biotechnology projects and also has patient investors who think long-term. In 1994, US$250 million was available to Medicon Valley. By 2000, this figure had increased to US$650 million and the invested capital in Medicon Valley was approximately US$160 million.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Ulf Åberg, Managing Director of Region Skåne

Ulf Åberg is currently Managing Director of Region Skåne. He completed his education at MBA Lund University, and at the Nordic Institute for Planning. After graduating, Ulf spent 15 years in leading positions in the regional economic development field, and a further five years working in Latin America for various international organisations.
Some of the positions he has held have included: Director of Planning on Malmöhus County Administrative Board; Director of Planning on Skåne County Administrative Board; and Director of Trade and Industry Department in Region Skåne. Ulf has also served as a Member of the Board of Directors of Teknopol AB, Euro Info Syd AB, and Öresund Identity Network.

spacer
Ulf Åberg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Altasciences Chosen by Respira Technologies, Inc. as Drug Product Manufacturing Partner for the World’s First Inhaled Nicotine Replacement Therapy (NRT)

Laval, Quebec, December 14, 2021 – Altasciences’ pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the world’s first inhaled smoking cessation therapy. This treatment uses RespiRx™, a vibrating mesh nebulizer (VMN) with a maintenance-free disposable cartridge that reduces and potentially eliminates the risk of patient misuse and non-compliance.
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement